Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Physiomics lowers forecasts amid contract delays

(Sharecast News) - Therapeutics and medicine-focussed mathematical modelling and data science company Physiomics said in an update on Friday that, despite a robust pipeline of potential new business, it had experienced delays in signing several large contracts. The AIM-traded firm said that as a result, the total income for the financial year ending 30 June was now anticipated to range between £0.6m and £0.65m.

Physiomics said it was currently in the final negotiation stages for two projects - one with an existing client and the other with a potential new client - with a combined value expected to be around £0.35m.

While the board expected the contracts to be signed in the current financial year, the majority of the revenue from the projects was now projected to be recognised in the next period, ending 30 June 2025.

As a result, the board said it had also adjusted its expectations for 2025 revenues accordingly.

To date, the company said it had secured £0.23m of revenue for 2025, with expectations for that to increase to over £0.5m on signing the two new contracts.

"Whilst we are clearly disappointed that the execution of these two large contracts has been delayed, we have a high level of confidence that they will be signed before the end of this financial year," said chief executive officer Dr Pete Sargent.

"Assuming that is achieved, and taking account of the anticipated value of these two contracts, the company would then be going into its next financial year with one of its highest ever levels of signed projects."

At 1100 BST, shares in Physiomics were down 16.33% at 1.25p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

RBC Capital lifts Centrica to 'outperform', shares rally
(Sharecast News) - RBC Capital Markets upgraded Centrica on Friday to 'outperform' from 'sector perform' and lifted the price target to 170p from 145p.
Jefferies reiterates 'buy' on National Grid, trims price target
(Sharecast News) - Jefferies trimmed its price target on National Grid on Friday as it reiterated its 'buy' rating on the energy infrastructure firm.
JPMorgan reiterates 'overweight' on Whitbread
(Sharecast News) - JPMorgan Cazenove reiterated its 'overweight' rating on Whitbread on Friday as it said it continues to be one of its key convictions, and sees the recent pullback - the shares are down 20% year-to-date - as "an opportunity to revisit the story".
Short-lived sunny spell helps boost UK supermarkets
(Sharecast News) - UK supermarket sales pushed higher in May, industry data showed on Friday, boosted by a brief spell of warmer weather.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.